Group 1 - The company held its 18th meeting of the 5th Board of Directors on August 19, 2025, with all 9 directors present, confirming the legality and validity of the meeting [2][5] - The board approved the proposal to cancel the supervisory board and amend the Articles of Association, transferring the supervisory board's powers to the audit committee of the board [3][39] - The proposal to amend the Articles of Association requires approval at the company's second extraordinary general meeting in 2025 [4] Group 2 - The board also approved the revision of 23 governance rules to enhance the company's governance structure, which will also be submitted for approval at the upcoming extraordinary general meeting [6][39] - A new management system for the departure of directors and senior management was established and disclosed [7] - The board nominated candidates for the 6th Board of Directors, including both non-independent and independent directors, all requiring approval at the extraordinary general meeting [9][15][39] Group 3 - The company announced the date and details for the second extraordinary general meeting, scheduled for September 4, 2025, at 14:30 [21][20] - Voting will be conducted through a combination of on-site and online methods, with specific timeframes for each [22][24] - The company will provide reminders to minority investors to ensure their participation in the voting process [27]
陕西康惠制药股份有限公司 第五届董事会第十八次会议决议公告